Open AccessA rare cutaneous adverse effect secondary to cabozantinib therapy
Author(s) -
Siona Growcott,
Alexandra Banner,
Adam Bray,
Serena Hilman
Publication year - 2018
Publication title -
oxford medical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.169
H-Index - 9
ISSN - 2053-8855
DOI - 10.1093/omcr/omy105
Subject(s) - cabozantinib , medicine , tyrosine kinase inhibitor , toxicity , adverse effect , dermatology , skin cancer , cancer , oncology
Cabozantinib is a tyrosine kinase inhibitor which is increasingly being used for the treatment of metastatic renal cell cancer. Skin toxicity such as palmar-plantar erythrodysesthesia is not uncommon with such agents. However, bullous skin reactions are not common and we report the case of a patient with metastatic renal cell cancer who experienced such cutaneous toxicity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom